Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn about a paper he co-authored with colleagues published in NPJ Breast Cancer:
“Proud to share our new Perspective in NPJ Breast Cancer, Nature Portfolio.
In this review, our group reflects on a concept we are deeply working on: how to better integrate baseline (pre-treatment) biology with a dynamic, on-treatment view of tumor evolution.
Baseline static biomarkers remain essential to guide initial decisions. But tumors evolve under therapeutic pressure, and capturing this evolution is critical if we want clinical strategies that are truly adaptive and biology-driven.
The work was led by Francesco Schettini, with Giuseppe Di Grazia (ESMO – European Society for Medical Oncology Fellow) as first author, and represents a strong collaborative effort across our team and collaborators in Spain, Italy and Germany.
It also offers a broader reflection on how academia and industry can better align to translate biological insight into real clinical impact. Congratulations to whole team for this thoughtful and forward-looking contribution. This direction is central to how we see the future of precision oncology.”
Title: Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology
Authors: Giuseppe Di Grazia, Rodrigo Sánchez-Bayona, Climent Casals-Pascual, Tomás Pascual, Daniele Generali, Alessandra Gennari, Paolo Vigneri, Nadia Harbeck, Javier Cortés, Aleix Prat, Francesco Schettini
You can read the full article in NPJ Breast Cancer.
More posts featuring Alex Prat.